Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check8 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.0 to v3.7.1; the page still displays a 403 error.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study content. This indicates the page is currently inaccessible.SummaryDifference18%

- Check50 days agoChange DetectedThe page now displays a new revision identifier: v3.6.6, replacing v3.6.5. This reflects a minor site-wide update that does not alter the study details or content.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page's revision label was updated to v3.6.5, replacing the previous v3.6.4 in the revision history.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4, reflecting an internal page version update. No user-facing study information appears to be altered.SummaryDifference0.0%

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.